Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 3Pain, Intractable 2Cancer Pain 2Spinal Surgery 1Pain Related to Cancer 1Mucositis 1Leukemia 1Breast Neoplasms 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1Adenocarcinoma 1

Interventions

Morphine 6nabiximols 4Oxycodone 3Fentanyl 3Methadone 2Hydromorphone 2Acetaminophen 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1resiniferatoxin 1naloxegol 1Tapentadol 1Sugars 1Standard of Care 1Lidocaine 1Inosine Monophosphate 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Cancer Pain × Methadone × Clear all
NCT05325164 2022-12-05

METHADOPT

Ottawa Hospital Research Institute

Phase 3 Withdrawn

Cancer Pain, Adenocarcinoma, Neoplasms

NCT00634010 2016-05-09

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

M.D. Anderson Cancer Center

Phase 3 Terminated
36 enrolled 6 charts

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡